A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy

J Law Med Ethics. 2017 Dec;45(4):692-697. doi: 10.1177/1073110517750609.

Authors

Frazer A Tessema¹, Jonathan J Darrow¹

Affiliation

¹ Frazer A. Tessema, B.A., is a research assistant with the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital. Jonathan J. Darrow, S.J.D., J.D., M.B.A., is a faculty member at Harvard Medical School and a member of PORTAL.

PMID: 30027797
DOI: 10.1177/1073110517750609

No abstract available

MeSH terms

Child
Clinical Trials, Phase II as Topic
Cytokines / metabolism
Drug Costs
Humans
Immunotherapy, Adoptive
Leukemia, B-Cell / therapy*
Receptors, Antigen, T-Cell / therapeutic use*
Remission Induction

Substances

Cytokines
Receptors, Antigen, T-Cell
tisagenlecleucel